Works matching IS 0284186X AND DT 2020 AND VI 59 AND IP 9


Results: 20
    1
    2
    3
    4
    5

    Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.

    Published in:
    Acta Oncologica, 2020, v. 59, n. 9, p. 1058, doi. 10.1080/0284186X.2020.1781249
    By:
    • Friedlaender, Alex;
    • Metro, Giulio;
    • Signorelli, Diego;
    • Gili, Alessio;
    • Economopoulou, Panagiota;
    • Roila, Fausto;
    • Banna, Giuseppe;
    • De Toma, Alessandro;
    • Camerini, Andrea;
    • Christopoulou, Athina;
    • Lo Russo, Giuseppe;
    • Banini, Marco;
    • Galetta, Domenico;
    • Jimenez, Beatriz;
    • Collazo-Lorduy, Ana;
    • Calles, Antonio;
    • Baxevanos, Panagiotis;
    • Linardou, Helena;
    • Kosmidis, Paris;
    • Mountzios, Giannis
    Publication type:
    Article
    6
    7
    8
    9

    An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry.

    Published in:
    Acta Oncologica, 2020, v. 59, n. 9, p. 1123, doi. 10.1080/0284186X.2020.1775289
    By:
    • Pouwels, Xavier G. L. V.;
    • Ramaekers, Bram L. T.;
    • Geurts, Sandra M. E.;
    • Erdkamp, Frans;
    • Vriens, Birgit E. P. J.;
    • Aaldering, Kirsten N. A.;
    • van de Wouw, Agnes J.;
    • Dercksen, M. W.;
    • Smilde, Tineke J.;
    • Peters, Natascha A. J. B.;
    • van Riel, J. M. G. H.;
    • Pepels, Manon J.;
    • Heijnen-Mommers, Jose;
    • Tjan-Heijnen, Vivianne C. G.;
    • de Boer, Maaike;
    • Joore, Manuela A.
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20